<DOC>
	<DOCNO>NCT00511667</DOCNO>
	<brief_summary>A multiple dose study assess safety pharmacokinetics investigational drug patient type 2 diabetes . The primary hypothesis study multiple daily MK-0941 subject T2DM without adequate control metformin sufficiently safe well tolerated permit continue clinical investigation .</brief_summary>
	<brief_title>A Multiple Dose Investigational Drug Study Patients With Type 2 Diabetes ( MK-0941-005 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Nonsmoking Male Female ( nonchild bear potential ) Diagnosis Type 2 Diabetes treat diet exercise alone less 3 oral antihyperglycemic agent Panel E ( MK0941 60 mg 2 meal day ) : diagnosis Type 2 Diabetes dose metformin great equal 1500 mg 8 week Subject insulin peroxisome proliferatoractivated receptor ( PPAR ) agonist Subject 3 oral antidiabetes medication Subject history type 1 diabetes Subject diagnosis glaucoma blind Subject trauma one eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>